NCT05389722View on ClinicalTrials.gov

A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 9, 2022

Primary Completion Date

November 12, 2022

Study Completion Date

November 12, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

CC-92480

Specified dose on specified days

DRUG

Rifampin

Specified dose on specified days

DRUG

Itraconazole

Specified dose on specified days

DRUG

Digoxin

Specified dose on specified days

DRUG

Rosuvastatin

Specified dose on specified days

Trial Locations (1)

75247-4968

Covance Clinical Research Unit - Dallas, Dallas

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05389722 - A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants | Biotech Hunter | Biotech Hunter